-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The study, published in the journal Science Advance, attempts to understand the underlying causes of the severity of neuroblastoma.
fact that all neuroblastomas come from cross-sensory neuroblasts makes them attractive drug targets.
neuroblastoma is a rare form of cancer that usually affects children under the age of five.
is that the severity of neuroblastoma can vary greatly from individual to individual.
survival rate of neuroblastoma is one of the lowest of all childhood cancers.
researchers speculated whether differences in the severity of neuroblastoma could be caused by different cell types at different stages of a child's development in the womb.
the emergence of single-cell mRNA sequencing makes it possible to verify this hypothesis.
For the study, the researchers analyzed the gene expression of 19,723 cancer cells and compared them with references to 57,972 developing adrenal cells in order to identify the types of cells produced by neuroblastoma and find new therapeutic targets.
, many cancer treatments have serious side effects on patients.
But in recent years, technological advances have allowed researchers to identify differences in biological processes within healthy human cells and cancer cells, such as the expression of specific genes, that can be used to attack cancer cells without affecting the patient's healthy cells.
Dr Karin Straathof, senior author of the study, said: "Neuroblastoma is an unusual cancer because some tumours can subside without intervention, but the disease still has the lowest five-year survival rate of any child.
this study fills an important gap in our understanding of neuroblastoma cells and reveals new therapeutic targets that I hope will lead to the development of new, less invasive therapies by targeting cross-sensory neuroblastocytes.
" Source: New drug targets for childhood cancer neuroblastomaed Original source: "Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell" Science Advances (2021). DOI: 10.1126/sciadv.abd3311
